UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2026
Commission File Number: 001-42907
Charming
Medical Limited
(Translation
of registrant’s name into English)
Units 1803-1806, 18/F, Hang Lung Centre
2-20 Paterson Street, Causeway Bay, Hong Kong
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
On November 5, 2026, Charming Medical Limited
issued a press release titled “Charming Medical Limited Announces Receipt of Nasdaq Delisting Determination Notice.” The press
release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.
EXHIBIT INDEX
| Exhibit No. |
|
Description |
| 99.1 |
|
Press Release Dated November 5, 2026 |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| Date: November 5, 2026 |
Charming Medical Limited |
| |
|
|
| |
By: |
/s/ Kit Wong |
| |
Name: |
Kit Wong |
| |
Title: |
Chief Executive Officer and
Chairman of the Board of Directors |
Exhibit 99.1
Charming Medical Limited Announces Receipt of
Nasdaq Delisting Determination Notice.
Hong Kong, Nov. 05, 2026 (GLOBE NEWSWIRE) --
Charming Medical Limited (Nasdaq: MCTA) (the “Company”), a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired
therapies and products, today announced that it received a delisting determination letter, dated October 29, 2026, from the Listing Qualifications
Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq Staff has determined to delist the Company’s
securities from Nasdaq.
On November 11, 2025, the U.S. Securities and
Exchange Commission (the “SEC”) issued an order suspending trading in the Company’s securities because of potential
manipulation in the securities of the Company effectuated through recommendations made to investors by unknown persons via social media
to purchase, hold, and/or sell the securities of the Company and to send screenshots documenting their transaction, which appear to be
designed to artificially inflate the price and trading volume of the securities of Company (the SEC’s order can be found at https://www.sec.gov/files/litigation/suspensions/2025/34-104176.pdf).
Following this, Nasdaq halted trading in the Company’s securities and has now determined to delist the Company’s securities
pursuant to Nasdaq Listing Rule IM-5101-4.
Nasdaq Listing Rule 5101 provides Nasdaq with
“broad discretionary authority over the initial and continued listing of securities in Nasdaq in order to maintain the quality of
and public confidence in its market, to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles
of trade, and to protect investors and the public interest.” Listing Rule IM-5101-4 further expands on this authority, allowing
Nasdaq “to exercise discretion to delist a company from Nasdaq based on the potential for one or more third parties to engage in
misconduct impacting a company’s securities where the SEC has implemented a temporary trading suspension.”
Following the Notice, the Company has and will
continue to consult with its legal counsel and other advisors to evaluate its next steps and will make further announcements as and when
appropriate. Unless the Company requests an appeal of this determination by November 5, 2026, trading of the Company’s securities
will be suspended at the opening of business on November 9, 2026. Nasdaq will subsequently file a Form 25-NSE with the SEC, which will
remove the Company’s securities from listing and registration on The Nasdaq Stock Market.
To date, Nasdaq has not communicated any findings
or determination that the Company engaged in wrongdoing in connection with the recent trading activity in the Company’s securities
or otherwise. The delisting determination does not affect the Company’s ongoing business operations or financial condition, and
the Company will continue to conduct its business in the ordinary course.
Following the removal from The Nasdaq Stock Market,
the Company’s securities may be eligible for trading in the over-the-counter (OTC) market. However, there can be no assurance that
an active or sustained secondary trading market will develop for the Company’s securities.
About Charming Medical Limited
Charming Medical Limited (the “Company”)
is a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products. The Company integrates TCM principles
with modern technology to enhance quality of life and promote holistic well-being. Through its four wellness centers in Hong Kong, the
Company offers a wide range of services, including womb-warming therapy, pelvic detox therapy, moxibustion, prenatal massage, and traditional
abdominal binding, designed to address women’s health issues such as menstrual irregularities, hormonal imbalance, and postpartum
recovery. Under its “Beauty Lab” brand, Charming Medical Limited also develops and distributes TCM-inspired supplements and
beauty products, such as uterine care patches, probiotic washes, and nourishing herbal formulations, aimed at improving women’s
constitution and vitality. In addition, the Company provides technical training, dietary therapy consultancy, and franchise opportunities
to extend its wellness philosophy to other practitioners and entrepreneurs. For more information, please visit https://charmingmed.com.
Forward-Looking Statement
This press release contains forward-looking statements.
Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying
assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,”
“will,” “intend,” “should,” “believe,” “expect,” “anticipate,”
“project,” “estimate,” or similar expressions that do not relate solely to historical matters, it is making forward-looking
statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the
actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements
are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors
discussed in the “Risk Factors” section of the registration statement and Form 20-F filed with the SEC. For these reasons,
among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional
factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes
no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
Investor Relations Contacts
Charming Medical Limited
Investor Relations
Tel: +852-3797-8461
Email: ir@hkbeautylab.com
